Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris

References

• Lee S, Coleman CI, Limone B, et al. Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis Rockville MD: Agency for Healthcare Research and Quality; 2012.
   Google Scholar
• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Psoriasis – Report by the Secretariat; 2014. Available from http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_18-en.pdf.
   Google Scholar
• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983–94.
   PubMed Web of Science ®Google Scholar
• Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the Management of Plaque Psoriasis. Waterloo, CA; 2009. Available from http://www.dermatology.ca/psoriasisguidelines.
   Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dsch Dermatol Ges. 2012;10:S1–S95.
   Web of Science ®Google Scholar
• National Clinical Guidelines Centre. Psoriasis: assessment and management; 2012. Available from http://www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-35109629621701.
   Google Scholar
• Bilac C, Ermertcan AT, Bilac DB, et al. The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol. 2009;75:551.
   PubMed Web of Science ®Google Scholar
• Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871–81. e1-30.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Swensen AR, Nyirady J, et al. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014;53:714–22.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Chouela EN, Mallbris L, et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: Post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol. 2015;29:1114–20.
   PubMed Web of Science ®Google Scholar
• Remrod C, Sjostrom K, Svensson A. Pruritus in psoriasis: a study of personality traits, depression and anxiety. Acta Derm Venereol. 2015;95:439–43.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969–73.
   PubMed Web of Science ®Google Scholar
• Reich A, Hrehorow E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90:257–63.
   PubMed Web of Science ®Google Scholar
• Amatya B, Wennersten G, Nordlind K. Patients' perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22:822–6.
   PubMed Web of Science ®Google Scholar
• Prignano F, Ricceri F, Pescitelli L, Lotti T. Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol. 2009;2:9–13.
   PubMedGoogle Scholar
• Reich A, Welz-Kubiak K, Rams L. Apprehension of the disease by patients suffering from psoriasis. Postepy Dermatol Alergol. 2014;31:289–93.
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Reich A, Wisnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat. 2002;10:221–6.
   PubMedGoogle Scholar
• Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156:1272–7.
   PubMed Web of Science ®Google Scholar
• Naegeli AN, Flood E, Tucker J, et al. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol. 2015;54:715–22.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology (Basel). 1998;197:326–34.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, de Hoop D, de Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology (Basel). 2000;200:292–8.
   PubMed Web of Science ®Google Scholar
• Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Research. 2014;14:559–68.
   PubMed Web of Science ®Google Scholar
• Martin SL, Dabade TS, Feldman ST. A red, scaly rash: how to recognize and treat psoriasis. J Clin Outcomes Manag. 2011;18:424–39.
   Google Scholar
• Reich A, Szepietowski JC. Clinical aspects of itch: psoriasis. In: Carstens E, Akiyana T, eds. Itch: Mechanisms and Treatment. Boca Raton, FL: Taylor & Francis Group, LLC; 2014. p. 33–46.
   Google Scholar
• Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014;70:390–1.
   PubMed Web of Science ®Google Scholar
• Reich A, Orda A, Wisnicka B, Szepietowski JC. Plasma neuropeptides and perception of pruritus in psoriasis. Acta Derm Venereol. 2007;87:299–304.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–44.
   PubMedGoogle Scholar
• Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; 2009. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf.
   Google Scholar
• Darsow U, Mautner VF, Bromm B, et al. [The Eppendorf Pruritus Questionnaire]. Hautarzt. 1997;48:730–3.
   PubMed Web of Science ®Google Scholar
• Darsow U, Scharein E, Simon D, et al. New aspects of itch pathophysiology: component analysis of atopic itch using the 'Eppendorf Itch Questionnaire'. Int Arch Allergy Immunol. 2001;124:326–31.
   PubMed Web of Science ®Google Scholar
• Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. Br J Dermatol. 2007;156:667–73.
   PubMed Web of Science ®Google Scholar
• Desai NS, Poindexter GB, Monthrope YM, et al. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol. 2008;59:234–44.
   PubMed Web of Science ®Google Scholar
• Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162:587–93.
   PubMed Web of Science ®Google Scholar
• Ograczyk A, Miniszewska J, Kepska A, Zalewska-Janowska A. Itch, disease coping strategies and quality of life in psoriasis patients. Postepy Dermatol Alergol. 2014;31:299–304.
   PubMed Web of Science ®Google Scholar
• Finlay A, Khan G. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–16.
   PubMed Web of Science ®Google Scholar
• Evers AW, Duller P, van de Kerkhof PC, et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol. 2008;158:101–8.
   PubMed Web of Science ®Google Scholar
• Strober BE, Nyirady J, Mallya UG, et al. Item-level psychometric properties for a new patient-reported psoriasis symptom diary. Value Health. 2013;16:1014–22.
   PubMed Web of Science ®Google Scholar
• Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: Prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92:502–7.
   PubMed Web of Science ®Google Scholar
• Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92:497–501.
   PubMed Web of Science ®Google Scholar
• Price A, Cohen DE. Assessment of pruritus in patients with psoriasis and atopic dermatitis: subjective and objective tools. Dermatitis. 2014;25:334–44.
   PubMed Web of Science ®Google Scholar
• Langner MD, Maibach HI. Pruritus measurement and treatment. Clin Exp Dermatol. 2009;34:285–8.
   PubMed Web of Science ®Google Scholar
• Reich A, Szepietowski JC. Pruitus intentisty assessment: challenge for clinicians. Expert Rev Dermatol. 2013;8:291–9.
   Google Scholar
• Stander S, Augustin M, Reich A, et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol. 2013;93:509–14.
   PubMed Web of Science ®Google Scholar
• Weisshaar E. Assessment of pruritus. Acta Derm Venereol. 2012;92:449–50.
   Web of Science ®Google Scholar
• Furue M, Ebata T, Ikoma A, et al. Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. Acta Derm Venereol. 2013;93:214–15.
   PubMed Web of Science ®Google Scholar
• Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 2011;63:S240–S52.
   PubMed Web of Science ®Google Scholar
• Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res. 2011;63:S263–S86.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Bagel J, Yamauchi P, et al. Fixed combination calcipotriene 0.005%/betamethasone dipropionate 0.064% aerosol foam provides rapid itch relief and improvements in itch-related sleep loss in psoriasis patients (PSO-FAST study). World Congress of Dermatology; June 8–13, 2015; Vancouver, Canada.
   Google Scholar
• Paul C, Stein Gold L, Warren R, et al. Superior efficacy of the fixed combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel in patients with psoriasis vulgaris – the Phase III PSO-ABLE study. European Academy of Dermatology and Venereology (EADV) Congress; October 7–11, 2015; Copenhagen, Denmark.
   Google Scholar
• Swinburn P, Lloyd A, Boye KS, et al. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health. 2013;16:1156–62.
   PubMed Web of Science ®Google Scholar
• Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the Psoriasis Quality of Life questionnaire. Dermatol Psychosom. 2002;3:171–9.
   Google Scholar
• Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66:e67–76.
   PubMedGoogle Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659–64.
   PubMed Web of Science ®Google Scholar
• Chularojanamontri L, Griffiths CE, Chalmers RJ. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol. 2013;133:1956–62.
   PubMed Web of Science ®Google Scholar
• Kirby B, Fortune DG, Bhushan M, et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. 2000;142:728–32.
   PubMed Web of Science ®Google Scholar
• Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369–75.
   PubMed Web of Science ®Google Scholar
• Zhu B, Edson-Heredia E, Guo J, et al. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol. 2014;171:1215–19.
   PubMed Web of Science ®Google Scholar
• Kopyciok ME, Stander HF, Osada N, et al. Prevalence and characteristics of pruritus: a one-week cross-sectional study in a German dermatology practice. Acta Derm Venereol. 2016;96:50–5.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers; 1988.
   Google Scholar
• Wainer H, Braun HI. Test Validity. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988 1988.
   Google Scholar